Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease: Results from the EMPRISE study

被引：0
|
作者：
Koenemann, Lisette [1 ]
Htoo, Phyo Than [2 ,3 ]
Patorno, Elisabetta [2 ,3 ]
Tesfaye, Helen [2 ,3 ]
Wexler, Deborah J. [4 ,5 ]
Glynn, Robert J. [2 ,3 ]
Schmedt, Niklas
Deruaz-Luyet, Anouk [6 ]
Schneeweiss, Sebastian [2 ,3 ]
Paik, Julie M. [2 ,3 ]
机构：
[1] Lilly Deutschland GmbH, Global Med Affairs, Bad Homburg, Germany
[2] HMS, BWH, Boston, MA USA
[3] Div Pharmacoepidemiol, Boston, MA USA
[4] HMS, MGH, Boston, MA USA
[5] MGH Diabet Ctr, Boston, MA USA
[6] Boehringer Ingelheim Int GmbH, Corp Dept Global Epidemiol, Ingelheim, Germany
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P21-09
引用
收藏
页码：S149 / S149
页数：1
相关论文
共 50 条
  • [21] Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes
    Almohareb, Sumaya N.
    Alfayez, Osamah M.
    Aljuaid, Shoroq S.
    Alshahrani, Walaa A.
    Bakhsh, Ghalia
    Alshammari, Mohammed K.
    Al Yami, Majed S.
    Alshaya, Omar A.
    Alomran, Abdullah S.
    Korayem, Ghazwa B.
    Almohammed, Omar A.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (21)
  • [22] Effectiveness and safety of empagliflozin in routine care patients: interim results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Bessette, L.
    Franklin, J.
    Najafzadeh, M.
    Wexler, D.
    Deruaz-Luyet, A.
    Brodovicz, K.
    Schneeweiss, S.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S145 - S146
  • [23] Effectiveness and Safety of Empagliflozin in Routine Care Patients: Interim Results from the EMPagliflozin compaRative effectiveness and SafEty (EMPRISE) Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Bessette, Lily G.
    Franklin, Jessica
    Najafzadeh, Mehdi
    Wexler, Deborah J.
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Schneeweiss, Sebastian
    DIABETES, 2020, 69
  • [24] GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
    Gorriz, Jose Luis
    Jose Soler, Maria
    Navarro-Gonzalez, Juan F.
    Garcia-Carro, Clara
    Jesus Puchades, Maria
    D'Marco, Luis
    Martinez Castelao, Alberto
    Fernandez-Fernandez, Beatriz
    Ortiz, Alberto
    Gorriz-Zambrano, Carmen
    Navarro-Perez, Jorge
    Jose Gorgojo-Martinez, Juan
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [25] Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in patients with type 2 diabetes and moderate chronic kidney disease
    Rossing, P.
    Fioretto, P.
    Clark, A.
    Jensen, A. B.
    Nazal, N. Belmar
    Tuttle, K. R.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S356 - S357
  • [26] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Shah, Raj C.
    Jones, W. Schuyler
    Gordon, Howard
    Hwang, Wenke
    Ayoub, Isabella
    Ford, Daniel
    Chamberlain, Alanna
    Rao, Ajaykumar
    Fonseca, Vivian
    Chang, Alexander
    Ahmad, Faraz
    Hung, Adriana
    Hunt, Kelly
    Butler, Javed
    Bosworth, Hayden B.
    Pagidipati, Neha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 696 - 708
  • [27] Cardiovascular effectiveness of empagliflozin versus glucagon-like peptide-1 receptor agonists or liraglutide in the emprise study
    Htoo, Phyo
    Tesfaye, Helen
    Paik, Julie
    Wexler, Deborah
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 99 - 100
  • [28] The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
    von Scholten, Bernt Johan
    Kreiner, Frederik Flindt
    Rasmussen, Soren
    Rossing, Peter
    Idorn, Thomas
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [29] GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
    Yu, Ji Hee
    Park, So Young
    Lee, Da Young
    Kim, Nan Hee
    Seo, Ji A.
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2022, 41 (02) : 136 - 149
  • [30] The impact of GLP-1 receptor agonists on metabolic control and diabetic kidney disease progression
    Venda, Joao
    Henriques, Andreia Dos Santos
    Monsanto, Alice
    Pompermayer, Micael
    Leal, Rita
    Alves, Rui
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1204 - I1204
12345